The two organizations first announced the acquisition in July.
Evolent officials initially predicted the deal would cost approximately $145 million. Officials said the final number is based on the closing price of Evolent’s stock, which traded at more than $24 per share on Tuesday when the deal was finalized.
According to the agreement, Evolent will acquire the majority of Valence, apart from its contracts serving state insurance co-ops. Those shares will be transferred to a separate entity owned by Valence shareholders, according to the article.
Evolent officials expect Valence to generate revenues between $80 and $85 million in 2016, according to the article.
More articles on transactions and valuations:
Philadelphia Eagles’ Carson Wentz partners with Sanford Health
Louisiana reaches deal with BRF hospital operator
OCH Hospital acquires Carthage Children’s Clinic
